Abstract
Hereditary angioedema (HAE) is a rare genetic disease resulting from a deficiency of C1 inhibitor (C1-INH) or mutations in F12 gene. In both cases, the changes lead to uncontrolled activation of the kallikrein-kinin system (KKS) culminating in excessive release of bradykinin (BK). HAE profoundly affects the quality of life, treatment is expensive and often inefficient. We propose a gene t…